DDInter822 DDInter1676
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Glasdegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Glasdegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Glasdegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Glasdegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levosalbutamol
Glasdegib {u} may lead to a major life threatening interaction when taken with {v} Bedaquiline
Glasdegib {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Bedaquiline
Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib